CRISPR Therapeutics AG Quarterly Weighted Average Number of Shares Outstanding, Basic from Q1 2016 to Q3 2024

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
CRISPR Therapeutics AG quarterly/annual Weighted Average Number of Shares Outstanding, Basic history and growth rate from Q1 2016 to Q3 2024.
  • CRISPR Therapeutics AG Weighted Average Number of Shares Outstanding, Basic for the quarter ending September 30, 2024 was 85.2M shares, a 7.33% increase year-over-year.
  • CRISPR Therapeutics AG annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 79.2M shares, a 1.9% increase from 2022.
  • CRISPR Therapeutics AG annual Weighted Average Number of Shares Outstanding, Basic for 2022 was 77.7M shares, a 2.37% increase from 2021.
  • CRISPR Therapeutics AG annual Weighted Average Number of Shares Outstanding, Basic for 2021 was 75.9M shares, a 15.2% increase from 2020.
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 85.2M +5.82M +7.33% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 84.9M +5.83M +7.37% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-05
Q1 2024 81.8M +3.12M +3.96% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 79.2M +1.47M +1.9% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-21
Q3 2023 79.4M +1.39M +1.79% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 79.1M +1.58M +2.04% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 78.7M +1.58M +2.05% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 77.7M +1.8M +2.37% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-21
Q3 2022 78M +1.73M +2.27% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 77.5M +1.69M +2.22% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 77.1M +2.09M +2.79% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 75.9M +4.67M +6.55% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-21
Q3 2021 76.3M +6.15M +8.76% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 75.8M +14.4M +23.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 75M +14.2M +23.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 71.3M +13.9M +24.2% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-16
Q3 2020 70.1M +15.3M +27.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 61.4M +8.23M +15.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 60.8M +8.75M +16.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-27
Q4 2019 57.4M +5.71M +11% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-16
Q3 2019 54.8M +7.44M +15.7% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-16
Q2 2019 53.2M +6.35M +13.5% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-16
Q1 2019 52.1M +6.22M +13.5% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-16
Q4 2018 51.7M +11.2M +27.6% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-12
Q3 2018 47.4M +7.3M +18.2% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-12
Q2 2018 46.8M +6.95M +17.4% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-12
Q1 2018 45.9M +6.15M +15.5% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-12
Q4 2017 40.5M +7.52M +22.8% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-25
Q3 2017 40.1M +34.8M +657% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-25
Q2 2017 39.9M +34.4M +632% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-25
Q1 2017 39.7M +34.2M +619% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-25
Q4 2016 33M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-08
Q3 2016 5.29M Jul 1, 2016 Sep 30, 2016 10-K 2018-03-08
Q2 2016 5.45M Apr 1, 2016 Jun 30, 2016 10-K 2018-03-08
Q1 2016 5.53M Jan 1, 2016 Mar 31, 2016 10-K 2018-03-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.